How to arrange the medication time of Platinib/Pujihua

Pralsetinib is a targeted drug mainly used to treat patients with non-small cell lung cancer (NSCLC) and thyroid cancer carrying RET gene fusion mutations. It helps prevent the growth and spread of cancer cells by inhibiting the activity of the RET protein, thus providing patients with new treatment options. When using platinib, patients should strictly follow the doctor's instructions on the medication schedule to ensure the maximum effect of the treatment.

The recommended dose of Platinib is400 mg once daily, and patients should take it on an empty stomach. To ensure absorption of the medication, it is very important that you should not eat at least 2 hours before or 1 hour after taking the medication. Taking medications on an empty stomach increases their bioavailability, thereby enhancing their therapeutic effects. The treatment plan with platinib should be continued until the patient's condition worsens or unacceptable toxicity occurs. In other words, discontinuation or dose adjustment should only be considered if patients experience severe side effects.

If a patient misses a dose of Platinib, it should be taken as soon as possible that day to ensure continuity of treatment is not affected. You can resume your normal daily dosing schedule the next day. If the patient experiences vomiting after taking the medication, he should avoid taking the dose again and continue taking subsequent doses according to the original medication plan. This is to avoid overdose and ensure therapeutic effectiveness.

The dosage and administration of Platinib are clinically proven to ensure patients achieve maximum results during treatment. Patients should undergo regular physical examinations while taking the medication to monitor the side effects and efficacy of the medication. It is expected that as more clinical data accumulates, platinib will gain wider application worldwide and provide new treatment opportunities for more patients.

Keyword tags: pralsetinib,Pralsetinib, RET gene fusion, targeted therapy, non-small cell lung cancer, thyroid cancer, fasting, drug dosage, treatment plan

Reference materials:https://en.wikipedia.org/wiki/Pralsetinib